A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation

Oncogene

Volumn 34, Issue 17, 2015, Pages 2215-2226

  Yan, Y ^a   Hein, A L ^a   Greer, P M ^a   Wang, Z ^a   Kolb, R H ^a,c   Batra, S K ^b   Cowan, K H ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ATM PROTEIN, HUMAN; ATR PROTEIN, HUMAN; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; ERBB4 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

G2 PHASE CELL CYCLE CHECKPOINT; GAMMA RADIATION; GENETICS; HUMAN; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; RADIATION RESPONSE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ATAXIA TELANGIECTASIA MUTATED PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASES; G2 PHASE CELL CYCLE CHECKPOINTS; GAMMA RAYS; HUMANS; M PHASE CELL CYCLE CHECKPOINTS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTOR, ERBB-4;

EID: 84939873145     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.167     Document Type: Article

References (51)

1. Kuntz K, O'Connell MJ. The G2 DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol Ther 2009; 8: 1433-1439.
2. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
3. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 2004; 14: 11.
4. Smits VA, Medema RH. Checking out the G(2)/M transition. Biochim Biophys Acta 2001; 1519: 1-12.
5. Rhind N, Furnari B, Russell P. Cdc2 tyrosine phosphorylation is required for the DNA damage checkpoint in fission yeast. Genes Dev 1997; 11: 504-511.
6. Kharbanda S, Saleem A, Datta R, Yuan ZM, Weichselbaum R, Kufe D. Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2. Cancer Res 1994; 54: 1412-1414.
7. O'Connell MJ, Raleigh JM, Verkade HM, Nurse P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 1997; 16: 545-554.
8. Lundgren K, Walworth N, Booher R, Dembski M, Kirschner M, Beach D. Mik1 and wee1 cooperate in the inhibitory tyrosine phosphorylation of cdc2. Cell 1991; 64: 1111-1122.
9. Parker LL, Atherton-Fessler S, Piwnica-Worms H. P107wee1 is a dual-specificity kinase that phosphorylates p34cdc2 on tyrosine 15. Proc Natl Acad Sci USA 1992; 89: 2917-2921.
10. Bulavin DV, Higashimoto Y, Demidenko ZN, Meek S, Graves P, Phillips C et al. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol 2003; 5: 545-551.
11. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
12. Prigent C, Dimitrov S. Phosphorylation of serine 10 in histone H3, what for? J Cell Sci 2003; 116: 3677-3685.
13. Xu B, Kastan MB. Analyzing cell cycle checkpoints after ionizing radiation. Methods Mol Biol 2004; 281: 283-292.
14. Hendzel MJ, Wei Y, Mancini MA, Van Hooser A, Ranalli T, Brinkley BR et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997; 106: 348-360.
15. Sauve DM, Anderson HJ, Ray JM, James WM, Roberge M. Phosphorylation-induced rearrangement of the histone H3 NH2-terminal domain during mitotic chromosome condensation. J Cell Biol 1999; 145: 225-235.
16. Xu B, Kim ST, Lim DS, Kastan MB. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol Cell Biol 2002; 22: 1049-1059.
17. Yan Y, Black CP, Cowan KH. Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 2007; 26: 4689-4698.
18. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol 2003; 22: 237-252.
19. Hersey P, Zhuang L, Zhang XD. Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model. In: Kwang WJ (ed) International Review of Cytology Vol. 251. Academic Press: New York, NY, 2006, pp 131-158.
20. Yamaguchi H, Chang SS, Hsu JL, Hung MC. Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene 2013; 33: 1073-1081.
21. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 2000; 79: 355-369.
22. Abbott DW, Holt JT. Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation. J Biol Chem 1999; 274: 2732-2742.
23. Tang D, Wu D, Hirao A, Lahti JM, Liu L, Mazza B et al. ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J Biol Chem 2002; 277: 12710-12717.
24. Kolb RH, Greer PM, Cao PT, Cowan KH, Yan Y. ERK1/2 signaling plays an important role in topoisomerase II poison-induced G2/M checkpoint activation. PLoS ONE 2012; 7: e50281.
25. Yan Y, Spieker RS, Kim M, Stoeger SM, Cowan KH. BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation. Oncogene 2005; 24: 3285-3296.
26. Yan Y, Greer PM, Cao PT, Kolb RH, Cowan KH. RAC1 GTPase plays an important role in gamma-irradiation induced G2/M checkpoint activation. Breast Cancer Res 2012; 14 : R60.
27. Yan Y, Haas JP, Kim M, Sgagias MK, Cowan KH. BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. J Biol Chem 2002; 277: 33422-33430.
28. Linggi B, Carpenter G. ErbB receptors: new insights on mechanisms and biology. Trends Cell Biol 2006; 16: 649-656.
29. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncogen 2012; 17: 1-16.
30. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncogen 2012; 17: 31-50.
31. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005; 23: 2445-2459.
32. Goldkorn T, Balaban N, Shannon M, Matsukuma K. EGF receptor phosphorylation is affected by ionizing radiation. Biochim Biophys Acta 1997; 1358: 289-299.
33. Lee H-C, An S, Lee H, Woo S-H, Jin H-O, Seo S-K et al. Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. Mol Cancer Res 2008; 6: 996-1002.
34. Kiyozuka M, Akimoto T, Fukutome M, Motegi A, Mitsuhashi N. Radiation-induced dimer formation of EGFR: implications for the radiosensitizing effect of cetuximab. Anticancer Res 2013; 33: 4337-4346.
35. Nyati MK, Maheshwari D, Hanasoge S, Sreekumar A, Rynkiewicz SD, Chinnaiyan AM et al. Radiosensitization by Pan ErbB inhibitor CI-1033 in vitro and in vivo. Clin Cancer Res 2004; 10: 691-700.
36. Liang K, Lu Y, Jin W, Ang KK, Milas L, Fan Z. Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Therap 2003; 2: 1113-1120.
37. Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y et al. EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 2008; 123: 209-216.
38. Subik K, Lee JF, Baxter L, Strzepek T, Costello D, Crowley P et al. The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 2010; 4: 35-41.
39. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21: 245-255.
40. Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001; 21: 3445-3450.
41. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001; 28: 80-85.
42. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science 1995; 267: 1782-1788.
43. Arteaga Carlos L, Engelman Jeffrey A. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014; 25: 282-303.
44. Jani JP, Finn RS, Campbell M, Coleman KG, Connell RD, Currier N et al. Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor. Cancer Res 2007; 67: 9887-9893.
45. Yan Y, Cao PT, Greer PM, Nagengast ES, Kolb RH, Mumby MC et al. Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response. Oncogene 2010; 29: 4317-4329.
46. Lee MS, Igawa T, Yuan TC, Zhang XQ, Lin FF, Lin MF. ErbB-2 signaling is involved in regulating PSA secretion in androgen-independent human prostate cancer LNCaP C-81 cells. Oncogene 2003; 22: 781-796.
47. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 1997; 15: 1191-1197.
48. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 2002; 9: 387-399.
49. Leach JK, Van Tuyle G, Lin PS, Schmidt-Ullrich R, Mikkelsen RB. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 2001; 61: 3894-3901.
50. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
51. Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 2012; 72: 3228-3237.